A preparation method of monoupivir

Monupivir was prepared by using cytidine as raw material and through hydroxylamineization, protection group, esterification and deprotection reactions, which solved the problems of single use of raw materials, complex operation, serious pollution and high cost in the existing technology, and achieved the Efficient and environmentally friendly monupivir preparation.

CN116041403BActive Publication Date: 2024-11-26CHENGDU ORGANOCHEM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210736138.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-29
Publication Date
2024-11-26
Estimated Expiration
2042-09-29

AI Technical Summary

Technical Problem

In the existing monupivir synthesis method, the raw materials are used in a single way, complex operation, serious pollution, high cost, and a large amount of waste.

Method used

Using cytidine as a raw material, monupivir is gradually prepared through hydroxylamineization, protection group, esterification and deprotection reactions, reducing waste generation and raw material costs, using cytidine with lower cost, and improving raw material utilization.

Benefits of technology

The high yield and low cost preparation of monupivir are achieved, reducing waste and wastewater production, and improving environmental protection and production efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116041403B_ABST
    Figure CN116041403B_ABST
Patent Text Reader

Abstract

In order to reduce waste generation and lower raw material costs, an embodiment of the present invention provides a method for preparing Monupivir, comprising: using cytidine as a raw material, sequentially undergoing hydroxylation reaction, protecting group addition reaction, esterification reaction, deprotection reaction, and purification to obtain Monupivir; the embodiment of the present invention uses cytidine as a raw material, sequentially undergoing hydroxylation reaction, protecting group addition reaction, esterification reaction, deprotection reaction, and purification to obtain Monupivir. By using cytidine with lower cost as a raw material, the above preparation method not only has a higher yield, but also a higher raw material utilization rate, and less subsequent waste and wastewater are generated, which is lower in cost and more environmentally friendly than the existing route.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for preparing monupivir. Background Art

[0002] Monopivir is a ribonucleoside analog that inhibits the replication of SARS-CoV-2, the pathogen of the novel coronavirus infection. Data show that monopivir can effectively reduce the risk of hospitalization and death of patients with early novel coronavirus infection by 30%, and is an effective means of early treatment for patients with mild novel coronavirus infection.

[0003] Most of the synthesis methods of monoprevir reported in the literature currently use uridine as the raw material, and adopt protection, esterification, substitution, hydroxylation, deprotection and other reactions for preparation and production. Propyl ketone is used for ortho-hydroxyl protection, and isobutyric anhydride or enzyme-catalyzed reaction is used for esterification reaction. There are problems such as single raw material use, complicated operation, severe pollution and high cost. Summary of the invention

[0004] The embodiment of the present invention provides a method for preparing monupivir to reduce waste generation and lower raw material costs.

[0005] The embodiment of the present invention is achieved through the following technical solutions:

[0006] An embodiment of the present invention provides a method for preparing monupivir, comprising:

[0007] Using cytidine as the raw material, monopivir is obtained after sequentially undergoing hydroxylation reaction, protecting group addition reaction, esterification reaction, deprotection reaction and purification.

[0008] Furthermore, cytidine is used as a raw material, and monoprevir is obtained after hydroxylation reaction, protection group addition reaction, esterification reaction, deprotection reaction, and purification; comprising:

[0009] Compound B is reacted with hydroxylamine in an aqueous alcohol solution to undergo hydroxylation reaction to obtain compound C;

[0010] Compound C and a protecting group reagent are reacted in a first solvent under the catalytic effect of acid or base and an inert gas atmosphere to protect the ortho-hydroxyl group of compound C through a protecting group reaction to generate compound D;

[0011] Compound D and an esterification reagent are subjected to an esterification reaction in a second solvent under alkaline conditions, a catalyst and an inert gas atmosphere to generate compound E;

[0012] Compound E undergoes a deprotection reaction with a deprotection agent in a third solvent, and after purification, monoprevir, i.e., compound A, is obtained.

[0013] Furthermore, the alcohol in the alcohol aqueous solution is one or more of ethanol, propanol, isopropanol and glycerol.

[0014] Furthermore, the first solvent, the second solvent and the third solvent are all one or more of dichloromethane, acetone, toluene, acetonitrile, hexane, ethyl acetate and tetrahydrofuran.

[0015] Furthermore, the structural formula of the protecting group reagent is:

[0016]

[0017] Wherein, R is C or Si; R1 is methyl, phenyl, ethyl or vinyl; R2 is methyl, phenyl, ethyl or vinyl.

[0018] Furthermore, the protecting group reagent is dichlorodimethylsilane, dichlorodiphenylmethane, 2,2-dimethoxypropane, acetone, dichlorodiethylsilane or divinyldichlorosilane.

[0019] Furthermore, the deprotection reagent is tetrabutylammonium fluoride, formic acid, hydrochloric acid or p-toluenesulfonic acid.

[0020] Furthermore, the catalyst is 4-dimethylaminopyridine or pyridine.

[0021] Furthermore, the structural formula of the esterification reagent is:

[0022]

[0023] Wherein, X is Cl, OH, Br or NH2.

[0024] Furthermore, the esterification reagent is isobutyric acid, isobutyryl chloride, isobutyric anhydride, isobutyryl bromide or isobutyramide.

[0025] Compared with the prior art, the embodiments of the present invention have the following advantages and beneficial effects:

[0026] A method for preparing monoprepivir according to an embodiment of the present invention uses cytidine as a raw material, and sequentially undergoes hydroxylation reaction, protecting group addition reaction, esterification reaction, deprotection reaction, and purification to obtain monoprepivir. By using cytidine with lower cost as a raw material, the above preparation method not only has a higher yield, but also a higher raw material utilization rate, and less subsequent waste and wastewater are generated, which is lower in cost and more environmentally friendly than the existing route. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to more clearly illustrate the technical solutions of the exemplary embodiments of the present invention, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0028] Figure 1 Schematic diagram of the process for preparing Monoupivir.

[0029] Figure 2 This is the hydrogen nuclear magnetic resonance spectrum data of Monouprivir prepared in Example 1.

[0030] Figure 3 This is the carbon nuclear magnetic resonance spectrum data of Monouprivir prepared in Example 1. DETAILED DESCRIPTION

[0031] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments and drawings. The exemplary embodiments of the present invention and their description are only used to explain the present invention and are not intended to limit the present invention.

[0032] In the following description, a large number of specific details are set forth in order to provide a thorough understanding of the present invention. However, it is apparent to one of ordinary skill in the art that these specific details are not necessarily employed to practice the present invention. In other embodiments, in order to avoid obscuring the present invention, well-known structures, circuits, materials, or methods are not specifically described.

[0033] Throughout the specification, references to "one embodiment," "an embodiment," "an example," or "an example" mean that a particular feature, structure, or characteristic described in conjunction with the embodiment or example is included in at least one embodiment of the present invention. Therefore, the phrases "one embodiment," "an embodiment," "an example," or "an example" appearing in various places throughout the specification do not necessarily all refer to the same embodiment or example. In addition, particular features, structures, or characteristics may be combined in one or more embodiments or examples in any suitable combination and / or sub-combination. In addition, it will be appreciated by those of ordinary skill in the art that the figures provided herein are for illustrative purposes and that the figures are not necessarily drawn to scale. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.

[0034] In the description of the present invention, the directions or positional relationships indicated by terms such as “front”, “rear”, “left”, “right”, “up”, “down”, “vertical”, “horizontal”, “high”, “low”, “inside” and “outside” are based on the directions or positional relationships shown in the accompanying drawings and are only for the convenience of describing the present invention and simplifying the description. They do not indicate or imply that the device or element referred to must have a specific direction, be constructed and operated in a specific direction. Therefore, they should not be understood as limiting the scope of protection of the present invention.

[0035] Example

[0036] In order to reduce waste generation and lower raw material costs, the present invention provides a method for preparing monupivir, comprising:

[0037] Using cytidine as the raw material, monopivir is obtained after sequentially undergoing hydroxylation reaction, protecting group addition reaction, esterification reaction, deprotection reaction and purification.

[0038] There are also methods for synthesizing Monupirvir using cytosine in the prior art. Cytosine needs to go through some processes to produce N4-hydroxycytidine, which is also an intermediate for synthesizing the target product compound A (monupirvir). The route of the embodiment of the present invention is mainly aimed at optimizing the synthesis route of Monupirvir. It is a method using cytidine as a starting material, and does not involve the subsequent synthesis of N4-hydroxycytidine from cytosine.

[0039] Thus, in the embodiment of the present invention, cytidine is used as a raw material, and monopivir is obtained after hydroxylation reaction, protecting group addition reaction, esterification reaction, deprotection reaction, and purification. By using cytidine with lower cost as a raw material, the above preparation method not only has a higher yield, but also a higher raw material utilization rate, and less subsequent waste and wastewater are generated, which is lower in cost and more environmentally friendly than the existing route.

[0040] Furthermore, cytidine is used as a raw material, and monoupivir is obtained after hydroxylation reaction, protecting group addition reaction, esterification reaction, deprotection reaction, and purification; Reference Figure 1 As shown, including:

[0041] S1. Compound B is reacted with hydroxylamine in an aqueous solution of alcohol to produce compound C;

[0042] S2. Compound C and a protecting group reagent are reacted in a first solvent under acid or base catalysis and an inert gas atmosphere to protect the ortho-hydroxyl group of compound C to generate compound D;

[0043] S3. Compound D and an esterifying agent are subjected to an esterification reaction under alkaline conditions, a catalyst and an inert gas atmosphere in a second solvent to generate a compound E;

[0044] S4. Compound E is subjected to a deprotection reaction with a deprotection agent in a third solvent, and monuprivir, i.e., compound A, is obtained after purification.

[0045] Compared with other routes, the preparation method of the present invention generates less waste. In other routes in the prior art that require enzyme-catalyzed esterification, the enzyme-catalyzed reaction process often requires the addition of a large amount of buffer.

[0046] As in patent CN112608357A, enzymes such as esterifying enzyme Novozyme 435 and protease BLP are used to catalyze esterification reaction. The purpose of adding buffer is mainly to affect the activity of enzyme in the change of reaction solution pH during enzyme catalytic reaction, and the price of selected catalytic esterifying enzyme is often too high. In order to improve the efficiency of enzyme catalytic reaction and improve the utilization rate of enzyme, it is often necessary to add buffer (phosphoric acid, hydrochloric acid, sodium hydroxide, potassium hydroxide, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, Tris HCl, etc.) and the means, which is also necessary for all monoprevir synthesis routes using enzyme catalytic reaction, if buffer is not added, the usage of enzyme will increase. In the subsequent treatment process, the addition of buffer will cause the generation of a large amount of waste water, which will cause cost increase in industrial production process.

[0047] The waste generated in the synthesis process of Monoupivir by the preparation method of the embodiment of the present invention is mainly organic wastewater and waste gas. Long-term contact between organic wastewater and waste gas during the production process may cause harm to the human body, and improper treatment of wastewater and waste gas or direct discharge will cause pollution to the environment. The preparation route of the embodiment of the present invention has fewer steps and is simple to operate. Compared with the traditional route, less organic wastewater is generated, and the pollution to the environment caused by wastewater treatment and waste gas discharge is smaller.

[0048] Furthermore, the alcohol in the alcohol aqueous solution is one or more of ethanol, propanol, isopropanol and glycerol.

[0049] Furthermore, the first solvent, the second solvent and the third solvent are all one or more of dichloromethane, acetone, toluene, acetonitrile, hexane, ethyl acetate and tetrahydrofuran.

[0050] Furthermore, the structural formula of the protecting group reagent is:

[0051]

[0052] Wherein, R is C or Si; R1 is methyl, phenyl, ethyl or vinyl; R2 is methyl, phenyl, ethyl or vinyl.

[0053] Furthermore, the protecting group reagent is dichlorodimethylsilane, dichlorodiphenylmethane, 2,2-dimethoxypropane, acetone, dichlorodiethylsilane or divinyldichlorosilane.

[0054] Furthermore, the deprotection agent is tetrabutylammonium fluoride, formic acid, hydrochloric acid or p-toluenesulfonic acid.

[0055] Furthermore, the catalyst is 4-dimethylaminopyridine or pyridine.

[0056] In the route adopted in the embodiment of the invention, esterase is not used to catalyze the esterification reaction. The esterification process uses 4-dimethylaminopyridine or pyridine to catalyze the reaction under the action of a base, so there is no need to add an additional buffer, thereby reducing the generation of wastewater.

[0057] Furthermore, the structural formula of the esterification reagent is:

[0058]

[0059] Wherein, X is Cl, OH, Br or NH2.

[0060] Furthermore, the esterification reagent is isobutyric acid, isobutyryl chloride, isobutyric anhydride, isobutyryl bromide or isobutyramide.

[0061] Example 1

[0062] A method for preparing monoupivir, comprising:

[0063] (1) Hydroxylation: 50.00 g (205.6 mmol) of cytidine (compound B), 50.612 g (308.4 mmol) of hydroxylamine sulfate, 400 mL of isopropanol, and 100 mL of distilled water were added to a 1 L three-necked round-bottom flask equipped with a stirrer and a thermometer. The mixture was stirred and heated to 70°C to dissolve the solid suspension. After 10 minutes, the reaction mixture became uniform. The reaction mixture was stirred at 70°C for 5 hours. The reaction was monitored by HPLC until cytidine ≤ 3%. Turn off the heating and allow the suspension to slowly cool to room temperature (25°C) in about 3 hours, then cool the internal temperature to -5°C in an ice-salt bath and stir for another 3 hours. The solid was separated by desolventization and filtration, washed with ice water (100 mL×3), and dried overnight in a vacuum oven (50°C) to obtain 47.71 g of a white crystalline solid (compound C) with a yield of 89.5%.

[0064] (2) Protection: In a 100 mL three-necked round-bottom flask equipped with a stirrer, a thermometer, and a condenser reflux tube, add 50 ml of dichloromethane, 5.18 g (20 mmol) of the hydroxylation product (Compound C), and 3.03 g (30 mmol) of triethylamine. Stirring is started under an argon atmosphere and dissolved at room temperature (25°C). 2.61 g (20.2 mmol) of dimethyldichlorosilane is added dropwise. The dropping speed is controlled so that the temperature during the dropping process does not exceed 35°C. After the dropping, the temperature is raised to 60°C and the reaction is kept warm for 3 hours. The reaction is stopped after HPLC detects that the reaction compound C is ≤3%. The reaction solution is extracted with ethyl acetate, and the organic phase is washed with saturated sodium bicarbonate. After drying and filtering with anhydrous sodium sulfate, the mixture is concentrated under reduced pressure and crystallized in n-heptane. It is dried overnight in a vacuum oven (50°C) to obtain 5.96 g of a white crystalline product (Compound D), with a yield of 94.5%.

[0065] (3) Esterification reaction: 20.00 g (63.42 mmol) of the above-mentioned protected product (Compound D), 32.09 g (317.10 mmol) of triethylamine, 3.87 g (31.71 mmol) of 4-dimethylaminopyridine and 400 ml of tetrahydrofuran were added to a 1000 mL three-necked round-bottom flask equipped with a stirrer, a thermometer and a condenser reflux tube under an argon atmosphere. The reaction flask was cooled to 0±5° C. in an ice bath. 14.87 g (139.56 mmol) of isobutyryl chloride was slowly added dropwise over 2 h, and the reaction was carried out at 0° C. for 6 h. The reaction was stopped when the HPLC detection of Compound D was less than or equal to 2%. The solvent was concentrated under reduced pressure, and crystallized in n-heptane, and dried overnight in a vacuum oven (50° C.) to obtain 20.62 g of a white crystalline product (Compound E) with a yield of 84.3%.

[0066] (4) Deprotection: Add 20 g (51.89 mmol) of compound E obtained by esterification reaction, 400 ml of tetrahydrofuran, 7.79 g (129.72 mmol) of acetic acid, and 33.92 g (129.72 mmol) of tetrabutylammonium fluoride to a 1L three-necked round-bottom flask equipped with a stirrer and a thermometer. Then stir the reaction at room temperature (25°C) for 5-6 hours until all the compound E is completely reacted. Extract the reaction solution with ethyl acetate, wash the organic phase with saturated sodium bicarbonate, dry and filter the organic phase, and concentrate under reduced pressure. Add 50 mL of ethanol and 100 mL of MTBE to the residue and heat until the residue is completely dissolved, then cool to room temperature and stir for 1 hour until all the solid is precipitated. Vacuum filter to obtain a solid product, wash the filter cake with 100 mL of MTBE, and dry it in a vacuum oven (50°C) overnight to obtain 13.38 g of a white crystalline product (compound A), with a yield of 78.3%.

[0067] Reference for structure confirmation of compound A Figure 2 and 3 As shown. Figure 2 and Figure 3 It can be seen that the white crystalline product prepared by the above preparation method is Monupivir.

[0068] The method used in Example 1 of the present invention uses less solvent and produces less wastewater, which can greatly save costs. Taking Example 3 of patent CN112608357A as an example, based on the given yield and material usage, the process produces about 6.69L of wastewater for every 1mol of esterification product (including about 0.49L of reaction solvent THF, about 2.45L of buffer solution, about 2.45L of water added during the extraction process, and about 1.3L of crystallization solvent and water. About 80% of the recovered solvent has been subtracted). In Example 1 of the present invention, the esterification process produces about 1.70L of wastewater (including 1.5L of reaction solvent and 0.2L of crystallization solvent) for every 1mol of esterification product. In comparison, the esterification process can produce about 13.4 tons less wastewater per ton of production than patent CN112608357A (considering that the solvent recovery is calculated at 80%).

[0069] Example 2

[0070] A method for preparing monoupivir, comprising:

[0071] (1) Hydroxylation: Same as Example 1.

[0072] (2) Protection: In a 100 mL three-necked round-bottom flask equipped with a stirrer, a thermometer, and a condenser reflux tube, 50 ml of acetone, 5.18 g (20 mmol) of the hydroxylation product (Compound C), 0.38 g (2 mmol) of p-toluenesulfonic acid monohydrate, and 2.40 g (23 mmol) of 2,2-dimethoxypropane were added, and the reaction was stirred at room temperature for 18 h under an argon atmosphere until HPLC detected that the reaction compound C was ≤ 3% and then the reaction was stopped. The acetone was removed by concentration under reduced pressure, and the residue was dissolved in ethyl acetate, then desolventized and filtered, and crystallized in n-heptane, and dried overnight in a vacuum oven (50° C.) to obtain 5.91 g of a white crystalline product (Compound D), with a yield of 98.7%.

[0073] (3) Esterification reaction: 20.00 g (63.42 mmol) of the above-mentioned protected product (Compound D), 32.09 g (317.10 mmol) of triethylamine, 3.87 g (31.71 mmol) of 4-dimethylaminopyridine and 400 ml of tetrahydrofuran were added to a 1000 mL three-necked round-bottom flask equipped with a stirrer, a thermometer and a condenser reflux tube under an argon atmosphere. The reaction flask was cooled to 0±5° C. in an ice bath. 14.87 g (139.56 mmol) of isobutyryl chloride was slowly added dropwise over 2 h, and the reaction was carried out at 0° C. for 6 h. The reaction was stopped when the HPLC detection of Compound D was less than or equal to 2%. The solvent was concentrated under reduced pressure, and crystallized in n-heptane, and dried overnight in a vacuum oven (50° C.) to obtain 19.56 g of a white crystalline product (Compound E) with a yield of 83.5%.

[0074] (4) Deprotection: Add 6.51 g (17.6 mmol) of the product compound E from the previous step and 100 ml of formic acid to a 200 ml round-bottom flask, stir the reaction mixture at room temperature for 3 h, and control the reaction by HPLC until the reaction is complete. Concentrate in vacuo to obtain a transparent light pink oily product. Add 30 ml of ethanol, then remove the solvent under reduced pressure, add 50 mL of MTBE and heat to dissolve. Then cool and crystallize at room temperature. Collect the solid product by vacuum filtration, wash the filter cake with MTBE, and dry it in a vacuum oven (50°C) overnight to obtain 4.34 g of a white crystalline product (compound A), with a yield of 74.9%.

[0075] Example 3

[0076] A method for preparing monoupivir, comprising:

[0077] (1) Hydroxylation: Same as Example 1.

[0078] (2) Protection: In a 500mL three-necked round-bottom flask equipped with a stirrer, a thermometer, and a condenser reflux tube, 200mL of acetone and 5.18g (20mmol) of the hydroxylation product (Compound C) were added, and 2.5mL of sulfuric acid was slowly added dropwise under stirring at room temperature. The reaction was allowed to proceed at room temperature until TLC detected that the reaction of the reaction compound C was complete, and then the reaction solution was neutralized with triethylamine, and then the reaction was stopped. The acetone was removed by concentration under reduced pressure, and the residue was dissolved in ethyl acetate, then desolventized and filtered, and crystallized in hexane, and dried overnight in a vacuum oven (50°C) to obtain 5.89g of a white crystalline product (Compound D), with a yield of 98.5%.

[0079] (3) Esterification reaction: In a 250 mL three-necked round-bottom flask equipped with a stirrer, a thermometer, and a condenser reflux tube, add 9.88 g (33 mmol) of the above-mentioned protected product (Compound D), 0.25 g (2 mmol) of 4-dimethylaminopyridine, and 110 ml of ethyl acetate under an argon atmosphere, and stir to dissolve. Then add 8.40 g (83 mmol) of triethylamine dropwise, and then add 6.33 g (40 mmol) of isobutyric anhydride dropwise, and control the dropwise addition speed not to be too fast. The reaction was stirred at room temperature for 8 h, and the reaction was stopped when HPLC detected that the compound D was less than or equal to 2%. The reaction solution was extracted with dichloromethane, and the organic phase was washed with a saturated sodium bicarbonate aqueous solution. The solvent was concentrated under reduced pressure, and crystallized in hexane. The filtered product was dried overnight in a vacuum oven (50° C.) to obtain 10.87 g of a white crystalline product (Compound E), with a yield of 89.1%.

[0080] (4) Deprotection: Add 5.92 g (16.0 mmol) of the product compound E from the previous step and 100 ml of formic acid into a 200 ml round-bottom flask. The reaction mixture was stirred at room temperature for 3 h. The reaction was controlled to be complete by HPLC. The reaction mixture was concentrated in vacuo to obtain a transparent light pink oily product. 30 ml of ethanol was added, and then the solvent was removed under reduced pressure, and 50 mL of MTBE was added and heated to dissolve. Then cooled and crystallized at room temperature. The solid product was collected by vacuum filtration, and the filter cake was washed with MTBE and dried in a vacuum oven (50°C) overnight to obtain 3.88 g of a white crystalline product (compound A) with a yield of 73.7%.

[0081] The specific implementation methods described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific implementation method of the present invention and is not intended to limit the scope of protection of the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A method for preparing monoupivir, characterized in that: Using cytidine as a raw material, monoupivir is obtained after sequentially undergoing hydroxylation reaction, protecting group addition reaction, esterification reaction, deprotection reaction, and purification; include: Compound B is reacted with hydroxylamine in an aqueous solution of alcohol to produce compound C; the compound B is The compound C is Compound C and a protecting group reagent are reacted in a first solvent under the catalytic effect of acid or base and an inert gas atmosphere to protect the ortho-hydroxyl group of compound C through a protecting group reaction to generate compound D; the compound D is Compound D and an esterification reagent are subjected to an esterification reaction in a second solvent under alkaline conditions, a catalyst and an inert gas atmosphere to generate a compound E; the compound E is Compound E is subjected to a deprotection reaction with a deprotection agent in a third solvent, and after purification, monouprivir, i.e., compound A, is obtained; The protecting group reagent is dichlorodimethylsilane, dichlorodiethylsilane or divinyldichlorosilane; The esterification reagent is isobutyric acid, isobutyryl chloride, isobutyryl bromide or isobutyramide.

2. The method for preparing monoupivir according to claim 1, characterized in that: The alcohol in the aqueous solution of alcohol is one or more of ethanol, propanol, isopropanol and glycerol.

3. The method for preparing monoupivir according to claim 1, characterized in that: The first solvent, the second solvent and the third solvent are all one or more of dichloromethane, acetone, toluene, acetonitrile, hexane, ethyl acetate and tetrahydrofuran.

4. The method for preparing monopivir according to claim 1, characterized in that: The deprotection reagent is tetrabutylammonium fluoride, formic acid, hydrochloric acid or p-toluenesulfonic acid.

5. The method for preparing monoupivir according to claim 1, characterized in that: The catalyst is 4-dimethylaminopyridine or pyridine.

6. The method for preparing monoupivir according to claim 1, characterized in that: The structural formula of the esterification reagent is: Wherein, X is Cl, OH, Br or NH2.